W-MEDICAL-STRATEGY-GROUP
8.10.2020 14:02:15 CEST | Business Wire | Press release
Since 2009, Korea has been promoting its medical competitiveness, and established a national medical brand titled “Smart Care, Medical Korea”, to represent the excellence of Korea’s medical services.
From 2009 to 2019, more than 2.76 million visitors from 190 countries around the world visited Korea to experience medical services. Also, Korea has provided a medical training program for international medical professionals from 31 different countries, sharing and expanding Korean medical system and resources across the world.
These efforts have been internationally recognized and received the “Health and Medical Tourism: Destination of the Year” award twice consecutively in 2018 and 2019 from the IMTJ Medical Travel Awards, a prestigious global medical tourism awards ceremony. In recognition of improving the reputation of Korea’s medical brands across the world and continuous dedication to enhancing healthcare, Korea was also awarded the “Porter Prize for Excellence in CSV”, named after a world-renowned business administration scholar, Michael E. Porter.
To address the recent global pandemic with the COVID-19, Medical Korea has renewed its brand to “Medical Korea, Where Your Days Begin Again” which emphasizes the humanitarian value of regaining the everyday life. Under this brand, Medical Korea will continue to stay at the forefront of achieving health and wellness for people around the world.
Korea Health Industry Development Institute (KHIDI) will announce the renewal of its brand and set a new direction for the healthcare industry during the COVID-19 era at the “Medical Korea Brand Proclamation Ceremony & Symposium”, held by the Ministry of Health and Welfare and organized by KHIDI, on October 14, 2020 (11:00~17:10, GMT+9).
The event will start with the keynote speech by Dr. Jerome Kim, Director General of the International Vaccine Institute (IVI), followed by presentations by Dr. Andrew Trister, Deputy Director of Digital Health and Innovation at Bill & Melinda Gates Foundation, and Hyung-gyoun (Harris) Byun, Vice President of KT. The presentations will shed light on the impact of the 4th industrial revolution in the medical service industry and will be aired live online. (https://www.medical-korea.org/eng/symposium/symposium.do )
About KHIDI
The Korea Health Industry Development Institute is a government-affiliated institution which provides the systematic and professional support for the improvement of public health and enhancement of the international competitiveness in the health industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005268/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Calvin Klein Fragrances announces ROSALÍA as the face of new euphoria elixirs19.2.2026 14:30:00 CET | Press release
Campaign fronted by the global superstar and brand ambassador explores the distinct universes of the three new parfums Calvin Klein, Inc., part of PVH Corp. [NYSE: PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE: COTY], today unveil GRAMMY® Award-winning singer-songwriter ROSALÍA as the face of euphoria elixirs, a new collection of three distinct parfum intense creations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219549836/en/ Calvin Klein Fragrances announces ROSALÍA as the face of new euphoria elixirs. A daring new chapter of the iconic euphoria franchise, euphoria elixirs are a sensorial exploration of confidence, pleasure and sensuality. Embodied by global icon and Calvin Klein ambassador ROSALÍA, the campaign fuses movement and vivid color into a captivating exploration of freedom without limits. Known for her genre-defying sound and commanding visual artistry, ROSALÍA channels the fragrances’ m
ExaGrid Achieves Customer Milestone19.2.2026 14:00:00 CET | Press release
5,000+ organizations worldwide are actively using ExaGrid Tiered Backup Storage ExaGrid®, the leader in Tiered Backup Storage, today announced that over 5,000 customers are actively using its backup storage behind leading backup applications such as Veeam, Commvault, NetBackup, Rubrik, Arcserve, Acronis, SQL Dumps, Oracle RMAN Direct, HYCU, and many other backup applications and utilities. ExaGrid has achieved many milestones, including: +81 NPS score The highest in the backup storage industry 300+ published backup storage customer success stories on its website More than all competitors combined 200+ Gartner Peer Insights reviews With a high rating of 4.8/5 stars 24 Industry Awards in the last 3 years More than any other backup storage provider Over 20 consecutive quarters with positive: Free Cash Flow, P&L and EBITDA “ExaGrid realized that using standard primary storage behind a backup application is not a strong solution, and with any level of retention it’s very expensive as well a
DCO Launches Global “Ctrl+Alt+Delete” Campaign to Combat Online Misinformation and Enhance Trust in Digital Economy19.2.2026 13:25:00 CET | Press release
The “Stop Online Misinformation” campaign marks the culmination of sustained global collaboration to strengthen trust in the safe and all-inclusive digital economy The Digital Cooperation Organization (DCO) has announced the launch of the “Stop Online Misinformation: Ctrl+Alt+Delete,” global campaign to counter online misinformation and strengthen trust in the digital economy, calling for coordinated action by governments, media, the private sector, and digital platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218141056/en/ DCO Launches Global “Ctrl+Alt+Delete” Campaign to Combat Online Misinformation and Enhance Trust in Digital Economy - (Photo: AETOSWire) The campaign represents the culmination of a year of sustained multilateral and multistakeholder engagement led by DCO to address misinformation as a growing economic, societal, and trust-related challenge. Underpinned by DCO’s Online Content Integrity initiat
Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme19.2.2026 13:00:00 CET | Press release
With preloaded global maps, intelligent route tools, and weeks-long battery life, the T-Rex Ultra 2 is made for those who seek boundaries only to push beyond Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the T-Rex Ultra 2, the latest and most advanced member of its rugged T-Rex lineup. As part of the T-Rex family, the T-Rex Ultra 2 is built for uncertainty—designed to remain reliable in conditions where plans, environments, and outcomes are never fully defined. Purpose-built for extreme environments, the T-Rex Ultra 2 combines premium materials, enhanced navigation capabilities, and extended battery life to support athletes and explorers tackling long, complex routes where preparation and reliability matter most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219679075/en/ Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme “With the T-Rex Ultra 2, we
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency19.2.2026 12:00:00 CET | Press release
Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal rangeSingle dose of YOLT-202 was well tolerated with a favorable safety profile YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced positive interim data from an investigator-initiated trial (IIT) of YOLT-202, the Company’s investigational in vivo base editing therapy, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) that demonstrated positive safety and tolerability as well as meaningful increases in AAT levels in evaluated patients treated with the 35 mg and 45 mg dose levels. “These interim findings mark an exciting and important milestone for YolTech and for patients living with severe AATD. The rapid, robust, and dose‑dependent increases in functional AAT levels observed in this study—particularly among individuals with the PiZZ genotype—underscore the transformative potential of in vivo base editing as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom